由于医疗保健和科技行业的广泛抛售,DiaSorin 和 bioMerieux 的股票在 2026 年 3 月 20 日大幅下跌,没有公司特定消息. DiaSorin and bioMerieux stocks dropped sharply on March 20, 2026, amid broad healthcare and tech sector sell-offs, with no company-specific news.

迪亚索林 (DSRLF) 和生物美力士 (BMXMF) 在2026年3月20日星期五的股价大幅下跌,在81.65美元收盘后,迪亚苏林开盘时为71.57美元,而生物美利克斯从12019美元降至12个月低点102.25美元. DiaSorin (DSRLF) and bioMerieux (BMXMF) both saw significant stock declines on Friday, March 20, 2026, with DiaSorin opening at $71.57 after closing at $81.65 and bioMerieux falling to a 12-month low of $102.25 from $120.19. 交易量很小,分别为100股和600股. Trading volumes were minimal, with 100 and 600 shares respectively. 两家公司都没有公布新的财务结果或重大发展. Neither company announced new financial results or major developments. 两股的交易均低于50日和200天移动平均值,分析师保持"持有"或"中等买入"共识评级. Both stocks trade below their 50-day and 200-day moving averages, and analysts maintain a "Hold" or "Moderate Buy" consensus rating. 随着医疗保健和技术股票的更广泛市场趋势而下降. The declines follow broader market trends affecting healthcare and technology stocks.